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1078–5Objectives. Post-operative haemorrhage is a recognised complication and independent predictor of outcome in complex
vascular surgery. The off-license administration of activated Recombinant Factor VII (rFVIIa) to treat haemorrhage in
other surgical settings has been investigated, but concerns over potential adverse events have limited its use in vascular
surgery. This article reports rFVIIa’s method of action and systematically reviews rFVIIa’s role in complex vascular
surgery.
Methods. A systematic literature search identified articles reporting on rFVIIa administration within vascular surgery
patients. Patient-specific data regarding transfusion requirements was extracted and pooled statistical analysis performed.
Results. 15 articles reporting 43 patients were identified. RFVIIa has been administered in open and endovascular pro-
cedures and in both elective and emergency settings. Major aortic surgery accounted for 75% of cases. The range of rFVIIa
administered as a cumulative dose was large, as was the variation in initial dose. Transfusion data from 9 patients was
pooled and analysed. Significant differences were found between pre- and post- rFVIIa for packed red cell transfusions
(mean 29.2 vs. 8.2, p¼ 0.015). Intra-arterial thrombosis was reported in 3 cases.
Conclusions. RFVIIa may reduce haemorrhage in selected vascular surgical patients. Randomized controlled trials are
justified to definitively investigate its role within this setting.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Complex vascular surgery, with or without extracor-
poreal circulatory support, is associated with altered
haemostasis and increased post-operative bleeding,
even in patients with normal preoperative coagula-
tion parameters.1,2 Excessive blood loss, and blood
product transfusion requirements, are two key inde-
pendent predictors of outcome in major vascular sur-
gery patients.3,4 Research into haemorrhage reduction
in this setting includes the use of antifibrinolytics (e.g.
aprotinin) and intra-operative autologous transfusion
devices.5e7 However these have met with limitedsponding author. Mr. O. Warren BSc (Hons) MRCS, Depart-
of BioSurgery and Surgical Technology, Imperial College,
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refractory haemorrhage in vascular surgical patients
therefore persists.
Recombinant factor VIIa (rFVIIa) (NovoSeven;
NovoNordisk, Bagsvaerd, Denmark) was first licensed
for the treatment of haemorrhage in patients with
hemophilia A or B with neutralizing auto-antibodies
(coagulation inhibitors) to factor VIII or IX.8,9 In 2005
the United States Food and Drug Administration in-
creased rFVIIa’s license to include surgical procedures
in the same patient group, and patients with congenital
factor VII (FVII) deficiency.10 The surgical literature
increasingly reports the off-license administration of
rFVIIa to arrest haemorrhage refractory to other inter-
ventions.11e13
Whilst off-label use of rFVIIa within vascular surgi-
cal practice has been reported, this has been predom-
inantly within case reports or series 14e18 or as part of
larger cohort studies of mixed patient groups,19e21r Surgery. Published by Elsevier Ltd. All rights reserved.
146 O. J. Warren et al.and thus the role of rFVIIa in vascular surgery is cur-
rently unclear. In this paper we describe the mecha-
nism of action of rFVIIa, systematically review the
available evidence on the efficacy, dosage, safety and
cost implications of rFVIIa use in vascular surgery,
and formulate proposals for future research.Mechanism of Action of rFVIIa
The molecular mechanisms by which rFVIIa induces
the formation of a stable haemostatic plug remain un-
clear. Whilst it is generally agreed that rFVIIa en-
hances thrombin generation at sites of tissue injury,
controversy exists regarding the mechanisms by
which this comes about, particularly the source and
role of the protein, Tissue Factor (TF).
In physiological conditions, TF is absent from vas-
cular cells that come into contact with flowing blood
and is present as an inactive pool on sub-endothelial
cells. Vessel injury exposes this TF to the blood, where
it binds and activates FVII. The resulting TF-FVIIa
complex catalyzes the conversion of factor X into its
active form (Xa), induces thrombin generation, and
leads to fibrin formation and platelet activation.
The situation differs in pathological conditions.
Within atherosclerotic plaques, vascular smooth mus-
cles cells, monocytes and endothelial cells have all
been reported to aberrantly express and expose TF
to the circulation.22 Not only has this been shown to
be a critical event in atherothrombosis, but this ex-
pression and exposition has been shown to occur at
higher levels in patients with symptomatic coronary
and carotid disease, suggesting a role for TF in plaque
instability.23,24 Elsewhere, pro-inflammatory cytokines
released during the acute phase response, have been
shown to induce the production and expression of
TF on circulating neutrophils and monocytes.25,26 Re-
cently, controversy has arisen over the presence, con-
centration and function of ‘micro-particles’ of TF
within circulating blood27; some authors have
reported the presence of physiologically active
blood-borne TF28e30 whilst others have refuted it’s
existence.31,32
Regardless of location, the exact role that TF plays
in Recombinant FVIIa’s mechanism of action requires
further clarification. Knowledge of the normal haemo-
static process, plus the fact that rFVIIa appears to
induce thrombosis at sites of tissue injury, led to the
hypothesis that rFVIIa acts via a TF-dependent mech-
anism.33e35 Whilst supported by various studies
using different models,36 the high plasma concentra-
tions of rFVIIa required to induce haemostasis suggest
that TF-dependent activation cannot be the soleEur J Vasc Endovasc Surg Vol 35, February 2008mechanism. RFVIIa has been shown to directly acti-
vate Factor X on phospholipid vesicles, activated
platelets or monocytes independently of TF,37e39 al-
though this process is much less efficient and has
not been replicated by all groups.40
It is likely that rFVIIA probably functions via a com-
bination of TF-dependent and TF-independent path-
ways. The level and location of TF expression in
patients undergoing vascular surgery are likely to be
significantly higher and more widespread than in nor-
mal subjects, due to their pre-existing atherosclerotic
disease as well as the acute physiological disruption
caused by major vessel surgery. Therefore the appro-
priateness of administering rFVIIa to these patients
requires careful review.Methods
Literature search
A Medline, Google Scholar, Embase, Ovid and
Cochrane database search was performed to identify
all studies concerned with the use of rFVIIa in vascu-
lar surgery. The following MeSH headings were used:
‘‘recombinant FVIIa’’, and ‘‘vascular diseases’’,
‘‘aorta’’, ‘‘haemorrhage’’, ‘‘aneurysm’’ and ‘‘surgery’’.
The ‘‘related articles’’ function was utilised to broaden
the search, and all abstracts, studies, and citations
scanned and reviewed. Based on the title and abstract
of the publication, we retrieved articles containing
clinical data on the use of rFVIIa. References of the ar-
ticles acquired were also searched manually. No lan-
guage restrictions were made. Laboratory and
animal studies were excluded. The latest date for
this search was 1st May 2007.
Inclusion and exclusion criteria
We included any article that reported on the adminis-
tration of rFVIIa to stop haemorrhage in patients who
had undergone vascular surgery. For the purpose of
this review, we defined ‘vascular surgery’ to include
intervention upon the descending thoracic aorta (dis-
tal to the left subclavian artery), the remainder of the
aorta distally and peripheral arteries. Aortic arch, val-
vular or coronary artery surgery was deemed to be the
domain of the cardiothoracic surgeon. This area has
been recently reviewed 11 and thus these patients or
studies were excluded. In one instance, peripheral
vascular intervention was required as a complication
of cardiothoracic surgery and this patient was in-
cluded as haemorrhage pertained to this portion of
the procedure. Articles that studied the effect of
147rFVIIa in Vascular SurgeryrFVIIa on a mixed cohort of patients, e.g. those in In-
tensive Care Units, were studied and data for vascular
patients involved in those studies was extracted as far
as possible. Publications or patients were excluded if
they involved complex multiple trauma or the pro-
phylactic impact of rFVIIa. Articles were classified
as case reports or series, retrospective database (or
chart) reviews, and clinical studies.Data extraction and validation of studies
Three reviewers (EA, IVH, and DL) independently
extracted the following data from each study: first au-
thor, year of publication, study population character-
istics, study type, number of subjects, pathology and
procedure type. Data was retrieved on the following
outcomes of interest: Dosage (initial and cumulative),
pre- and post-intervention transfusion requirements,
adverse events (stroke, myocardial infarction and
other thromboembolic effects) and mortality.Data analysis
Outcome data was heterogeneous, and in some cases
unavailable, and this prevented a formal meta-
analysis being performed. However, where articles
reported individual patient-specific data regardingFig. 1. ‘Systematicblood product requirements prior to and after RFVIIa
infusion this was extracted and a pooled analysis per-
formed. Data are expressed either as raw count and
percentages or as mean value plus or minus standard
deviation. Kolmogorov-Smirnov test was performed
to test normality of distributions and revealed the
data to be normally distributed. Thus Paired Samples
T-Test was performed. All statistical analysis was per-
formed using SPSS 14.0 (SPSS Inc., Chicago, IL).Results
Study identification
Fig. 1 outlines the systematic search strategy and re-
sults. 377 publications were identified of which 357
were excluded following title and abstract review. 21
publications were investigated in full. Of these, 6 fur-
ther articles failed to meet our inclusion criteria and 1
study was excluded due to duplication in a report
published by the same group one year earlier.41 1 fur-
ther study was identified from a detailed reference
check. 15 articles were therefore included in our
study, 5 purely on vascular patients 14e18 and the re-
maining 10 regarding mixed populations containing
some vascular patients.19e21,42e48 Of the 15 articles, 5
were case reports or series,15e18,42 and 10 were retro-
spective database or chart reviews.14,19e21,43e48Search Strategy’.
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Table 1. Case Mix
Procedure Number (%)
Thoracoabdominal Aortic Surgery 7 (15.9)
Descending thoracic reconstruction 4
Descending thoracic, aorto-femoral and aorto-iliac
reconstruction
1
Thoracoabdominal aneurysm repair 1
Allograft replacement of infected descending
thoracic prosthesis
1
Abdominal Aortic Surgery 26 (59.1)
Suprarenal aneurysm repair 9
Open infrarenal aneurysm repair
Post-operative leak 2
Ruptured 2
Elective 2
Unspecified 6
Endovascular infrarenal aneurysm repair 2
Re-do Aorto-bifemoral bypass grafting 2
Aorto-iliac pseudoaneurysm ligation &
axillo-femoral bypass grafting
1
Non-Aortic or Non-specified Vascular Surgery 11 (25)
‘Major vascular procedure’ 4
Evacuation of post-operative haematoma
and repair of leak
3
Femoro-femoral crossover graft
(following type a aortic dissection)
1
‘Perioperative haemorrhage’ 1
Inferior vena caval thrombus removal and repair 1
Local infusion into false aneurysm 1
148 O. J. Warren et al.Case mix and patient demographics
The 15 articles reported on the administration of
rFVIIa to a total of 273 patients, of whom 43 had un-
dergone vascular surgery as previously defined. The
patients ranged from 39 to 83 years of age, 51%
were male, 26% female and in 23% the gender of the
patient was not declared.
The variety of procedures performed upon rFVIIa-
treated patients is outlined in Table 1. One patient re-
ceived rFVIIa after two different operations separated
by a 34 day period on the Intensive Care Unit,16 and
thus 44 procedural episodes are described in 43 pa-
tients. Unsurprisingly major thoracoabdominal or ab-
dominal aortic (both supra- and infrarenal) surgery
accounts for the vast majority of cases (75%). RFVIIa
has been administered in both elective18,48 and emer-
gency43 settings, to assist in the management of
perioperative complications, such as evacuation of
post-operative haematoma14 and repair of leak,42 and
in both open and endovascular procedures. One ma-
jor venous injury has been treated with rFVIIa,19 and
one patient had rFVIIa administered via a standard
catheter directly into a false aneurysm of the
descending thoracic aorta which had developed fol-
lowing thoracoabdominal aortic replacement.17
It was not possible to ascertain any accurate data
on the proportion of patients who had a declared de-
gree of pre-operative coagulopathy e.g. secondary to
hepatic disease, or anticoagulant or antiplatelet ther-
apy, predominantly because this was not stated in
the paper. However, three patients who received
major thoracic surgery underwent intra-operative car-
diopulmonary bypass, a recognised contributor to
peri-operative coagulopathy.49
Studies were searched to find any potential conflicts
of interest.None of the authors of thefifteen articles had
a financial arrangement with NovoNordisk.Total 44 (100)Dosage and frequency of administration
To allow data synthesis, we arbitrarily chose three
dosing levels of rFVIIa (see Table 2). The frequency
of rFVIIa administration was variable. Whilst some
groups prescribed only a single bolus 17e19 others ad-
ministered further doses if bleeding failed to stop.42,48
Therefore if patients received multiple doses, their
cumulative dose per kilogram body weight was re-
corded. The range of rFVIIa administered as a cumula-
tive dose was large (24 mg/kg e 360 mg/kg,
mean¼ 87.6 mg/kg) as was the variation in initial
dose (24 mg/kg e 120 mg/kg), and the total number
of doses (1 - 4). 59.1% of the patients within the seriesEur J Vasc Endovasc Surg Vol 35, February 2008had documented cumulative doses  90 mg/kg. The
mode dose was 90 mg/kg, the recommended dose in
haemophiliacs. The timing of administration, and
the criteria upon which the decision to do so was
made are frequently unclear. Some groups rely on sur-
geon and haemaologist ‘discretion’,14,21whilst others
specify the receipt of specific quantities of blood prod-
ucts by the patient.19 RFVIIa is manufactured in vials
of 1.2, 2.4 and 4.8 mg and is expensive (approaching
US$1/mg),50 and this appears to have led some centres
to utilise a ‘best-fit’ dosing regimen to avoid opening
more vials than necessary.44,48
Table 2. Variations in Dosing
Dosing (n¼ 44) Frequency (%)
Low Dose (< 60 mg/kg) 15 (34.1)
MideDose (60e90 mg/kg) 11 (25)
High Dose (> 90 mg/kg) 6 (13.6)
Undisclosed 12 (27.2)
Total 44 (100)
149rFVIIa in Vascular SurgeryEffect on haemorrhage
Whilst the majority of articles reported some reduc-
tion in blood loss, either as witnessed by the clini-
cian 18,47 or a reduction in the need for further blood
products,46 this was not a uniform finding.48 Further-
more, this was frequently a subjective assessment. 5 ar-
ticles presented patient-specific transfusion data, both
pre- and post-rFVIIa administration, on 9 different
patients.15,16,42,43,48 This data, along with mean and
standard deviation is presented in Table 3. A statisti-
cally and clinically significant reduction in packed
red cell transfusions following rFVIIa administration
was demonstrated ( p¼ 0.015), as was a reduction of
borderline statistical significance in platelet trans-
fusions (p¼ 0.057). No significant effect on fresh
frozen plasma or cryoprecipitate administration was
found. To ensure the findings were not related to the
papers studied, regression analysis was performed,
taking into account the article from which the data
was extracted. A group effect (using rFVIIa¼ yes as
an independent group variable and blood product
loss as dependent variable) was detected.Adverse events and mortality
Patient specific thromboembolic adverse event data
was not available for 62% of the cohort, and thus cal-
culation of an estimated adverse event rate would be
inappropriate. Intra-arterial thrombosis was reportedTable 3. Blood Product Requirements Pre- and Post-RFVIIa adminis
Patients Pre-rFVIIa
PRC
Post-rFVIIa
PRC
Pre-rFVIIa
Plts
Po
Plt
1. Pugh et al.42 29 40 2 4
2. Pugh et al.42 14 4 2 3
3. Cheng et al.15 17 0 32 0
4. Clark et al.48 27 6 1 1
5. Clark et al.48 28 14 2 2
6. Clark et al.48 25 6 1 1
7. Raux et al.16 66 2 51 0
8. Raux et al.16 18 0 20 0
9. Aggarwal et al.43 39 2 37 6
Mean Units ( S.D) 29.2 15.7 8.2 12.6 16.4 19.3 1.9
PRC¼ Packed Red Cells, Plts¼ Platelets, FFP¼ Fresh Frozen Plasma,in 3 patients, the risk of which may be increased in
vascular patients due to rFVIIa’s proposed mecha-
nism of action. It is worth noting however that these
cases were all reported by the same group, who ad-
ministered rFVIIa alongside human factor VIII-von
Willebrand factor concentrate and/or human fibrino-
gen, both of which increase the risk of coagulation
and make it unclear as to how much these events
are attributable to rFVIIa.45 16.3% of patients in the
cohort were reported to have died as a result of refrac-
tory haemorrhage, due predominantly to two studies,
one of which reported a 22% mortality rate 14 and the
other 100%.48Discussion
We have synthesised all of the available data within
the surgical literature on the administration of rFVIIa
to vascular patients suffering from haemorrhage re-
fractory to other conditions. By combining data origi-
nally reported in case reports or series, we have
demonstrated a clinically significant reduction in
blood and platelet transfusion requirements following
the administration of rFVIIa, a finding supported by
work in other surgical settings.12,13 Whilst our find-
ings must be interpreted cautiously, as these cases
are highly heterogeneous and there is an inherent
publication bias in non-comparative reports, we feel
they justify more research being performed in this set-
ting. This may help to eradicate the significant varia-
tion in practice we have demonstrated.
Ever since Kenet et al. reported the successful use of
rFVIIa in military trauma in 1999,51 research has been
undertaken in most surgical specialities to identify
any potential role for rFVIIa. Vascular surgery lagged
behind the other surgical specialities in this regard.
One reason for this may be theoretical concern regard-
ing the exacerbation of conditions mediated by TF ex-
posure to the circulation. Atherosclerotic plaquestration
st-rFVIIa
s
Pre-rFVIIa
FFP
Post-rFVIIa
FFP
Pre-rFVIIa
Cryo
Post-rFVIIa
Cryo
18 22 10 40
5 8 0 10
19 0 0 0
8 4 10 0
8 7 10 10
4 4 10 10
64 0 0 0
9 0 0 0
32 4 50 0
 2.1 18.6 19.2 5.4 6.9 10 15.8 7.8 13
Cryo¼Cryoprecipate, S.D¼ Standard Deviation.
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150 O. J. Warren et al.express TF, and both surgical injury and extracorporeal
circulation up-regulate systemic TF expression. Thus
patients undergoing major vascular surgery who re-
ceive rFVIIa may be at increased risk of unwanted sys-
temic thrombosis. These concerns arenot unwarranted;
A recent review of thromboembolic complications in
patients treated with rFVIIa reported to the FDA data-
base from 1999 to end 2004 suggested an increased
rate in those treated for unlabelled conditions,10 an
alarming result considering the morbidity and mortal-
ity from events such as stroke and myocardial infarc-
tion is so high. Furthermore, whilst an estimated
adverse event rate for the cohort was not possible in
our review due to absence of data, three patients were
identified who suffered intra-arterial thrombosis
following rFVIIa administration. However, similar the-
oretical concerns also apply to cardiac surgical patients.
This groupwas recently reviewed byWarren et al., who
aggregated the available data within cardiac surgical
patients treatedwith rFVIIa for refractoryhaemorrhage
and founda thromboembolic adverse event rate of 5.3%
for adult patients.11 This figure talliedwith that of Levy
et al. who reviewed 13 NovoNordisk-sponsored clini-
cal trials of rFVIIa in patients with coagulopathy secon-
dary to anti-coagulation, cirrhosis or severe traumatic
injury and found an adverse thromboembolic event
rate of 6% with no significant difference between
treated patients and placebo ( p¼ 0.57).52 Similarly a re-
cent randomized controlled trial of rFVIIa in trauma
patients did not find an increased risk of thromboem-
bolic events in the treatment group.53
Recommendations for the administration of rFVIIa
in major vascular surgery have been made previously
by Shander et al. 54 Based on an expert panel’s experi-
ence and a literature review they deemed the use of
rFVIIa as a rescue therapy to be ‘appropriate’ in thoracic
aortic surgery if significant clotting factor replacement
had been attempted, but suggested that the evidence
for its use in abdominal aortic surgery was less certain.
They suggested a dose of 41 to 90 mg/kg but we have
demonstrated a significant range of dosage currently
in reported practice. Similar recommendations were
made byGoodnough and colleagues,who advised cau-
tion in thosewith a history of vascular disease.55Whilst
it is difficult for us tomake clear evidence-based recom-
mendations regarding the appropriate indications for
rFVIIa in vascular surgery patient, there seems little ev-
idence to suggest a dose of greater than 90 mg/kg is any
more efficacious than that recommended by these
groups. Furthermore, in all cases where rFVIIa has
been reported to be effective adequate clotting re-
placement therapy has been undertaken prior to ad-
ministration, a practice supported by physiological
knowledge of it’s mechanism of action.Eur J Vasc Endovasc Surg Vol 35, February 2008The key for vascular surgeons when considering
the risk-benefits of rFVIIa administration likely lies
in the clinical situation; we would argue that on occa-
sion some vascular patients have life threatening
bleeding so severe as to warrant the consideration of
any therapy that may potentially prevent mortality.
This viewpoint is supported by Roberts who advo-
cated rFVIIa for life-threatening refractory haemor-
rhage in most scenarios, despite sometimes the
absence of controlled clinical trials.56
Limitations and recommendations for
further research
The major limitation of this systematic review and
pooled data analysis is the paucity of current evi-
dence; the number of patients within the literature is
small and they are derived from 15 different papers,
all of which are retrospective and non-comparative.
Therefore we are unable to perform meta-analysis.
However, the primary value of our systematic review
and critique of the available literature is to make the
vascular surgical community aware of rFVIIa’s pro-
posed method of action, highlights it’s potential role
in haemorrhage refractory to all other interventions
and outline the deficiencies within the literature,
thus guiding future research. To this end we have for-
mulated recommendations using the ‘EPICOT’ guide-
lines.57 Firstly, having reviewed all the data, we
believe that well-designed, randomized controlled tri-
als are required to definitively answer questions on
the cost effectiveness, appropriate dosing regime,
and safety profile of rFVIIa. With the justifiable con-
cerns regarding inappropriate intra-arterial thrombo-
sis, trials must initially focus on patients in extremis,
in whom all other efforts to staunch haemorrhage
have been exhausted. This will allow rFVIIa to be, at
least initially, compared to placebo, and avoid the con-
fusion in results interpretation that may arise if rFVIIa
is given in combination with other pro-coagulants,
such as Factor VIII.45 Outcomes must include subse-
quent requirement for transfusion, with strict proto-
cols for triggering blood product administration in
place prospectively, thromboembolic adverse event
rates and 30-day mortality. Any study should also
include a cost-effectiveness analysis.Conclusion
Recombinant factor VIIa is a potent pro-haemostatic
agent, which vascular surgeons should consider as
a potential therapeutic agent in patients with severe
haemorrhage refractory to conventional treatments.
151rFVIIa in Vascular SurgeryHowever, administration of rFVIIa is not without risk,
and should only occur in line with current literature
guidelines. Well-designed randomized controlled tri-
als are required to fully elucidate the cost effective-
ness, appropriate dosing regime, and safety profile
of rFVIIa within vascular surgery patients.Acknowledgments
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